Top-News

Aeglea BioTherapeutics News

Keine aktuellen Kursdaten verfügbar
WKN: A2AG5H
ISIN: US00773J1034
Typ: Aktie

Aeglea BioTherapeutics News

07.09.23 - PR Newswire
Aeglea BioTherapeutics Announces Reverse Stock Split
Aeglea BioTherapeutics Announces Reverse Stock Split PR Newswire
05.09.23 - PR Newswire
Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones
Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-​Jones PR Newswire
11.08.23 - PR Newswire
Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results
Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results PR Newswire
27.07.23 - PR Newswire
Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma
Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma PR Newswire
23.06.23 - PR Newswire
Aeglea BioTherapeutics Announces Grant of Inducement Awards
Aeglea BioTherapeutics Announces Grant of Inducement Awards PR Newswire
22.06.23 - PR Newswire
Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics
Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics PR Newswire
11.05.23 - PR Newswire
Aeglea BioTherapeutics Reports First Quarter 2023 Financial Results
Aeglea BioTherapeutics Reports First Quarter 2023 Financial Results PR Newswire
12.04.23 - PR Newswire
Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternatives
Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to ...
17.03.23 - PR Newswire
Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
02.03.23 - PR Newswire
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates PR Newswire
06.01.23 - PR Newswire
Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency
Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency PR Newswire
02.12.22 - PR Newswire
Aeglea BioTherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Aeglea BioTherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
30.11.22 - PR Newswire
Aeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive Officer
Aeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive Officer PR Newswire
15.11.22 - PR Newswire
Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer
Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer PR Newswire
03.11.22 - PR Newswire
Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates
Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates PR Newswire
19.10.22 - PR Newswire
Aeglea BioTherapeutics Hosting Key Opinion Leader Webinar on Classical Homocystinuria and Pegtarviliase's Potential Role in Treatment
Aeglea BioTherapeutics Hosting Key Opinion Leader Webinar on Classical Homocystinuria and Pegtarviliase's Potential Role in Treatment PR Newswire
04.10.22 - PR Newswire
Aeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria Program
Aeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria Program PR Newswire
29.08.22 - PR Newswire
Aeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022
Aeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022 PR Newswire
24.08.22 - PR Newswire
Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring
Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring PR Newswire
19.08.22 - PR Newswire
Thinking about buying stock in Volcon, Aeglea Bio Therapeutics, StoneCo, Party City, or FuelCell Energy?
Thinking about buying stock in Volcon, Aeglea Bio Therapeutics, StoneCo, Party City, or FuelCell Energy? PR Newswire

Newssuche

Videos

newspaper
26.04.24 +6,31%
Technical Trading: Gold Long freitags
Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »